Back to today’s briefing

Story perspectives

Australia Approves Lecanemab: Hope for Early Alzheimer's

9/30/2025

27 2

Summary

Story summary

Lecanemab gained approval from the Therapeutic Goods Administration (TGA) in Australia for early Alzheimer's, similar to donanemab.
It may slow progression but does not cure Alzheimer's, with about 27% slower progression shown in trials.
Costs around A$40,000 annually and is not subsidized by the Pharmaceutical Benefits Scheme; MRI monitoring is required.
Experts emphasize early diagnosis and equitable access.

1 of 1

Story summary

Lecanemab gained approval from the Therapeutic Goods Administration (TGA) in Australia for early Alzheimer's, similar to donanemab.
It may slow progression but does not cure Alzheimer's, with about 27% slower progression shown in trials.
Costs around A$40,000 annually and is not subsidized by the Pharmaceutical Benefits Scheme; MRI monitoring is required.
Experts emphasize early diagnosis and equitable access.